Cargando…

A recent development of new therapeutic agents and novel drug targets for cancer treatment

Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its...

Descripción completa

Detalles Bibliográficos
Autores principales: Kifle, Zemene Demelash, Tadele, Meklit, Alemu, Eyerusalem, Gedamu, Tadele, Ayele, Akeberegn Gorems
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725032/
https://www.ncbi.nlm.nih.gov/pubmed/34992782
http://dx.doi.org/10.1177/20503121211067083
_version_ 1784626032819568640
author Kifle, Zemene Demelash
Tadele, Meklit
Alemu, Eyerusalem
Gedamu, Tadele
Ayele, Akeberegn Gorems
author_facet Kifle, Zemene Demelash
Tadele, Meklit
Alemu, Eyerusalem
Gedamu, Tadele
Ayele, Akeberegn Gorems
author_sort Kifle, Zemene Demelash
collection PubMed
description Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its stage. Thus, this review aimed to summarize a recent development of new therapeutic agents and novel drug targets for the treatment of cancer. Several obstacles stand in the way of effective cancer treatment and drug development, including inaccessibility of tumor site by appropriate drug concentration, debilitating untoward effects caused by non-selective tissue distribution of chemotherapeutic agents, and occurrence of drug resistance, which leads to cross-resistance to a variety of drugs. Resistance to treatment with anticancer drugs results from multiple factors and the most common reason for acquiring drug resistance is marking and expelling drugs that prevent cancer cells to be targeted by chemotherapeutic agents. Moreover, insensitivity to drug-induced apoptosis, alteration, and mutation of drug target and interference/change of DNA replication are other main causes of treatment failure.
format Online
Article
Text
id pubmed-8725032
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-87250322022-01-05 A recent development of new therapeutic agents and novel drug targets for cancer treatment Kifle, Zemene Demelash Tadele, Meklit Alemu, Eyerusalem Gedamu, Tadele Ayele, Akeberegn Gorems SAGE Open Med Review Despite recent advances in cancer diagnosis, prevention, detection, as well as management, the disease is expected to be the top cause of death globally. The chemotherapy approach for cancer has become more advanced in its design, yet no medication can cure enough against all types of cancer and its stage. Thus, this review aimed to summarize a recent development of new therapeutic agents and novel drug targets for the treatment of cancer. Several obstacles stand in the way of effective cancer treatment and drug development, including inaccessibility of tumor site by appropriate drug concentration, debilitating untoward effects caused by non-selective tissue distribution of chemotherapeutic agents, and occurrence of drug resistance, which leads to cross-resistance to a variety of drugs. Resistance to treatment with anticancer drugs results from multiple factors and the most common reason for acquiring drug resistance is marking and expelling drugs that prevent cancer cells to be targeted by chemotherapeutic agents. Moreover, insensitivity to drug-induced apoptosis, alteration, and mutation of drug target and interference/change of DNA replication are other main causes of treatment failure. SAGE Publications 2021-12-23 /pmc/articles/PMC8725032/ /pubmed/34992782 http://dx.doi.org/10.1177/20503121211067083 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Kifle, Zemene Demelash
Tadele, Meklit
Alemu, Eyerusalem
Gedamu, Tadele
Ayele, Akeberegn Gorems
A recent development of new therapeutic agents and novel drug targets for cancer treatment
title A recent development of new therapeutic agents and novel drug targets for cancer treatment
title_full A recent development of new therapeutic agents and novel drug targets for cancer treatment
title_fullStr A recent development of new therapeutic agents and novel drug targets for cancer treatment
title_full_unstemmed A recent development of new therapeutic agents and novel drug targets for cancer treatment
title_short A recent development of new therapeutic agents and novel drug targets for cancer treatment
title_sort recent development of new therapeutic agents and novel drug targets for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725032/
https://www.ncbi.nlm.nih.gov/pubmed/34992782
http://dx.doi.org/10.1177/20503121211067083
work_keys_str_mv AT kiflezemenedemelash arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT tadelemeklit arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT alemueyerusalem arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT gedamutadele arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT ayeleakeberegngorems arecentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT kiflezemenedemelash recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT tadelemeklit recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT alemueyerusalem recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT gedamutadele recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment
AT ayeleakeberegngorems recentdevelopmentofnewtherapeuticagentsandnoveldrugtargetsforcancertreatment